RG
INFI

Redmile Group’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Redmile Group’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-590,100
Closed -$4.99M – 69
2015
Q3 		$4.99M Buy
+590,100
New +$5.44M 0.38% 41

Other funds holding INFI

ACM
Americafirst Capital Management Roseville, California $74M AUM 30.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group's INFI Position: Q4 2015 in Review

Redmile Group sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2015, closing a stake of 590,100 shares — an estimated $4.99M sold.

Redmile Group first reported a position in INFI in Q3 2015 and held it in 1 quarter. The position peaked at $4.99M in Q3 2015. 115 funds tracked by Wall St. Rank hold INFI as of Q4 2015.

  • Redmile Group reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • Redmile Group sold 590,100 Infinity Pharmaceuticals, Inc. shares in Q4 2015, an estimated $4.99M.
  • Redmile Group first reported a position in Infinity Pharmaceuticals, Inc. in Q3 2015 and held it in 1 quarter.
  • Redmile Group's Infinity Pharmaceuticals, Inc. position peaked at $4.99M in Q3 2015.
  • 115 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2015.

Based on Redmile Group's 13F filing for Q4 2015, filed 16 Feb 2016.